RTTR - リタ―・ファ―マシュ―ティカルズ (Ritter Pharmaceuticals Inc.) リタ―・ファ―マシュ―ティカルズ



symbol RTTR
会社名 Ritter Pharmaceuticals Inc (リタ―・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Ritter Pharmaceuticals Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company''s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient''s health. The Company''s compound RP-G28 is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate RP-G28 an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.   リタ―・ファ―マシュ―ティカルズは、米国の臨床段階の製薬会社。消化器系統で乳糖(ラクト―ス)の消化酵素(ラクタ―ゼ)が減少して生じる諸症状の治療薬を開発する。また、胃腸の健康状態を全般的に改善するための方法および組成物を提供する。本社はカリフォルニア州ロサンゼルス。   Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat digestive disorders and gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. The company was founded by Andrew J. Ritter and Ira E. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA.
本社所在地 1880 Century Park East Suite 1000 Los Angeles CA 90067 USA
代表者氏名 Ira E. Ritter アイラE.リッター
代表者役職名 Executive Chairman of the Board Chief Strategic Officer
電話番号 +1 310-203-1000
設立年月日 38047
市場名 NASDAQ Small Cap
ipoyear 2015年
url www.ritterpharmaceuticals.com
nasdaq_url https://www.nasdaq.com/symbol/rttr
EBITDA EBITDA(百万ドル) -9.89111
終値(lastsale) 1.94
時価総額(marketcap) 10737199.66
時価総額 時価総額(百万ドル) 9.29819
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) -2.71429
当期純利益 当期純利益(百万ドル) -12.93596
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Ritter Pharmaceuticals Inc revenues was not reported. Net loss increased 54% to $5.6M. Higher net loss reflects Research and Development increase from $1.2M to $2.7M (expense) General and administrative increase of 21% to $2.8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.85 to -$1.11.


 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 リタ―・ファ―マシュ―ティカルズ RTTR Ritter Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)